Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases, announced that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for its pipeline product dusquetide in the treatment of Behcet's disease. This milestone marks a significant step forward for the company and for patients living with this rare inflammatory condition.
Behcet's disease is a chronic, relapsing systemic vasculitis that can cause painful oral and genital ulcers, skin lesions, arthritis, and potentially severe ocular, neurological, and vascular complications. With limited treatment options, there is a high unmet medical need for new therapies. Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body's innate immune system rather than suppress it outright. This mechanism offers a novel approach to managing inflammatory diseases.
The positive COMP opinion paves the way for the European Commission to grant orphan drug designation for dusquetide in Behcet's disease. Orphan drug designation provides incentives to encourage the development of treatments for rare diseases, including protocol assistance, reduced regulatory fees, and up to 10 years of market exclusivity following approval. "We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program," said Soligenix CEO and president Christopher J. Schaber, PhD. "Behcet's disease is an area of unmet medical need, and this designation is an important step in advancing the program."
For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the EMA not only validates a drug's scientific rationale but can also unlock development incentives that accelerate its path forward. Soligenix's achievement underscores the potential of dusquetide to address a significant gap in treatment options for Behcet's disease.
The company's newsroom provides the latest updates relating to SNGX at https://ibn.fm/SNGX. This development highlights Soligenix's commitment to advancing therapies for rare diseases and areas of unmet medical need.
